JP2020504607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504607A5 JP2020504607A5 JP2019533514A JP2019533514A JP2020504607A5 JP 2020504607 A5 JP2020504607 A5 JP 2020504607A5 JP 2019533514 A JP2019533514 A JP 2019533514A JP 2019533514 A JP2019533514 A JP 2019533514A JP 2020504607 A5 JP2020504607 A5 JP 2020504607A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- cdr
- amino acid
- adam9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127121 immunoconjugate Drugs 0.000 claims description 105
- 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 claims description 49
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 43
- 239000012634 fragment Substances 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 102000054116 human ADAM9 Human genes 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 5
- 229910052708 sodium Inorganic materials 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 2
- 108010056243 alanylalanine Proteins 0.000 description 16
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 16
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 8
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 8
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 8
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 8
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 8
- 201000007750 congenital bile acid synthesis defect Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 4
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 4
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 4
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 4
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 4
- FSHURBQASBLAPO-WDSKDSINSA-N Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)N FSHURBQASBLAPO-WDSKDSINSA-N 0.000 description 4
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 4
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 description 4
- SJUXYGVRSGTPMC-IMJSIDKUSA-N Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O SJUXYGVRSGTPMC-IMJSIDKUSA-N 0.000 description 4
- 0 CC(C)IN*CNC(C)(C)C Chemical compound CC(C)IN*CNC(C)(C)C 0.000 description 4
- -1 D-Phe-Phe-Lys Chemical compound 0.000 description 4
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 4
- VHLZDSUANXBJHW-QWRGUYRKSA-N Gln-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHLZDSUANXBJHW-QWRGUYRKSA-N 0.000 description 4
- MRVYVEQPNDSWLH-XPUUQOCRSA-N Gln-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O MRVYVEQPNDSWLH-XPUUQOCRSA-N 0.000 description 4
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 4
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 description 4
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 4
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 4
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 description 4
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 4
- JHKXZYLNVJRAAJ-WDSKDSINSA-N Met-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(O)=O JHKXZYLNVJRAAJ-WDSKDSINSA-N 0.000 description 4
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 4
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 4
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 4
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 description 4
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 description 4
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 4
- 108010068380 arginylarginine Proteins 0.000 description 4
- 108010036533 arginylvaline Proteins 0.000 description 4
- 108010054155 lysyllysine Proteins 0.000 description 4
- 108010024607 phenylalanylalanine Proteins 0.000 description 4
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- 108010039491 Ricin Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000022136 colorectal lymphoma Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- QLWSUEDEGARQCO-UHFFFAOYSA-N CCC(CC(N1CCNC(CCNC(CNC(CNC(CNC(CCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O Chemical compound CCC(CC(N1CCNC(CCNC(CNC(CNC(CNC(CCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O QLWSUEDEGARQCO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438488P | 2016-12-23 | 2016-12-23 | |
| US62/438,488 | 2016-12-23 | ||
| US201762480201P | 2017-03-31 | 2017-03-31 | |
| US62/480,201 | 2017-03-31 | ||
| PCT/US2017/067823 WO2018119196A1 (en) | 2016-12-23 | 2017-12-21 | Immunoconjugates targeting adam9 and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504607A JP2020504607A (ja) | 2020-02-13 |
| JP2020504607A5 true JP2020504607A5 (enExample) | 2021-02-04 |
| JP7170642B2 JP7170642B2 (ja) | 2022-11-14 |
Family
ID=61025051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533514A Active JP7170642B2 (ja) | 2016-12-23 | 2017-12-21 | Ａｄａｍ９を標的とする免疫コンジュゲート及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20210388102A1 (enExample) |
| EP (1) | EP3558391B1 (enExample) |
| JP (1) | JP7170642B2 (enExample) |
| CN (1) | CN110267685B (enExample) |
| CY (1) | CY1125181T1 (enExample) |
| DK (1) | DK3558391T3 (enExample) |
| ES (1) | ES2912266T3 (enExample) |
| HR (1) | HRP20220550T1 (enExample) |
| HU (1) | HUE058664T2 (enExample) |
| LT (1) | LT3558391T (enExample) |
| MD (1) | MD3558391T2 (enExample) |
| PL (1) | PL3558391T3 (enExample) |
| PT (1) | PT3558391T (enExample) |
| RS (1) | RS63154B1 (enExample) |
| SI (1) | SI3558391T1 (enExample) |
| SM (1) | SMT202200182T1 (enExample) |
| TW (1) | TWI783957B (enExample) |
| WO (1) | WO2018119196A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201934187A (zh) | 2018-01-12 | 2019-09-01 | 美商免疫遺傳股份有限公司 | 抗體藥物結合、純化、及調配之方法 |
| JP2021528471A (ja) * | 2018-06-26 | 2021-10-21 | イミュノジェン・インコーポレーテッド | Ａｄａｍ９を標的とする免疫コンジュゲート、及び、その使用の方法 |
| TW202102270A (zh) | 2019-03-21 | 2021-01-16 | 美商伊繆諾金公司 | 製備細胞結合劑-藥物結合物之方法 |
| CN113661172A (zh) | 2019-03-29 | 2021-11-16 | 伊缪诺金公司 | 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物 |
| EP3958977B1 (en) | 2019-04-26 | 2023-09-13 | ImmunoGen, Inc. | Camptothecin derivatives |
| CN110713983B (zh) * | 2019-11-04 | 2022-06-10 | 深圳市体内生物医药科技有限公司 | 一种表达透明质酸酶的免疫细胞及其应用 |
| US20240165256A1 (en) | 2021-03-08 | 2024-05-23 | Immunogen, Inc. | Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer |
| CN118684724A (zh) | 2023-03-22 | 2024-09-24 | 映恩生物制药（苏州）有限公司 | 连接子及其在配体药物偶联物中的应用 |
| AU2024244721A1 (en) | 2023-03-24 | 2025-10-23 | Duality Biologics (Shanghai) Co., Ltd. | Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| CN120058950A (zh) * | 2023-11-28 | 2025-05-30 | 昆山新蕴达生物科技有限公司 | 抗adam9的抗体及其用途 |
| TW202540201A (zh) * | 2023-12-14 | 2025-10-16 | 大陸商四川科倫博泰生物醫藥股份有限公司 | Adam9結合蛋白及其用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DK1252192T3 (da) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
| EP1142910A1 (en) | 2000-04-07 | 2001-10-10 | Jürgen Prof. Dr. Frey | Inhibitors for the formation of soluble human CD23 |
| US20030091568A1 (en) | 2000-04-07 | 2003-05-15 | Jurgen Frey | Inhibitors for the formation of soluble human CD23 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| JP2005528082A (ja) | 2001-12-18 | 2005-09-22 | モンドバイオテック・ラボラトリーズ・アンスタルト | 間質性肺疾患の治療を向上させるためのインターフェロンγ又はパーフェニドンと分子診断薬との新規医薬組成物 |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US20040092466A1 (en) | 2002-11-11 | 2004-05-13 | Isis Pharmaceuticals Inc. | Modulation of ADAM9 expression |
| DE60336149D1 (de) | 2002-08-16 | 2011-04-07 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| DE10337368A1 (de) * | 2003-08-08 | 2005-03-03 | Technische Universität Dresden | Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| WO2005091823A2 (en) | 2004-03-01 | 2005-10-06 | The Regents Of The University Of California | The use of lunasin peptide as a transcriptional activator to prevent cancer and related methods for treatment, monitoring and prognosis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| NZ556561A (en) | 2005-02-02 | 2011-08-26 | Macrogenics West Inc | Adam-9 modulators |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| CL2007001536A1 (es) | 2006-05-30 | 2008-01-25 | Genentech Inc | Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b. |
| WO2007143752A2 (en) | 2006-06-09 | 2007-12-13 | The Regents Of The University Of California | Targets in breast cancer for prognosis or therapy |
| KR101443214B1 (ko) | 2007-01-09 | 2014-09-24 | 삼성전자주식회사 | 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이 |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| GB2453589A (en) | 2007-10-12 | 2009-04-15 | King S College London | Protease inhibition |
| US8101361B2 (en) | 2008-03-10 | 2012-01-24 | National Jewish Health | Markers for diagnosis of pulmonary inflammation and methods related thereto |
| JP2011516081A (ja) | 2008-04-07 | 2011-05-26 | ザイモジェネティクス， インコーポレイテッド | トロンビンアクチベーター組成物ならびにそれを作製および使用する方法 |
| US20090285840A1 (en) * | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
| HUE034763T2 (en) | 2008-04-30 | 2018-02-28 | Immunogen Inc | Crosslinkers and their use |
| CN102083461B (zh) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| US20110129450A1 (en) | 2008-08-01 | 2011-06-02 | Orly Lazarov | Method of promoting neurogenesis by modulating secretase activities |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| WO2010053539A2 (en) | 2008-11-05 | 2010-05-14 | The Texas A&M University System | Methods for detecting colorectal diseases and disorders |
| JP2012510821A (ja) | 2008-12-04 | 2012-05-17 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
| SG173152A1 (en) | 2009-02-05 | 2011-08-29 | Immunogen Inc | Novel benzodiazepine derivatives |
| MX2011012794A (es) | 2009-06-03 | 2012-05-08 | Immunogen Inc | Metodos de conjugacion. |
| WO2011100362A1 (en) | 2010-02-11 | 2011-08-18 | University Of Southern California | Modified adam disintegrin domain polypeptides and uses thereof |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| ES2623057T3 (es) | 2010-04-15 | 2017-07-10 | Medimmune Limited | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas |
| KR20190089048A (ko) | 2011-02-15 | 2019-07-29 | 이뮤노젠 아이엔씨 | 컨쥬게이트의 제조방법 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
| WO2013049704A2 (en) | 2011-09-28 | 2013-04-04 | Armune Biosciences, Inc. | Method and system of particle-phage epitope complex |
| US20140342946A1 (en) | 2011-12-31 | 2014-11-20 | Moni Abraham Kuriakose | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
| US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| WO2014108480A1 (en) | 2013-01-09 | 2014-07-17 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles |
| HK1218930A1 (zh) | 2013-02-08 | 2017-03-17 | Abbvie Stemcentrx Llc | 新型多特异性结构 |
| EP2985346A4 (en) | 2013-04-08 | 2016-05-25 | Mitsubishi Rayon Co | MICROARRAY FOR THE EVALUATION OF EYE DISEASES AND EVALUATION METHODS OF EYE DISEASES |
| WO2014186364A2 (en) | 2013-05-13 | 2014-11-20 | Tufts University | Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer |
| US20160138113A1 (en) | 2013-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis |
| US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| US10988531B2 (en) * | 2014-09-03 | 2021-04-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US9381256B2 (en) | 2014-09-03 | 2016-07-05 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| US9669102B2 (en) | 2014-09-03 | 2017-06-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| JP2018500049A (ja) | 2014-11-11 | 2018-01-11 | アムニクス オペレーティング インコーポレイテッド | ターゲティングｘｔｅｎコンジュゲート組成物およびそれを作製する方法 |
| SI3313845T1 (sl) | 2015-06-29 | 2021-01-29 | Immunogen, Inc. | Konjugati spremenjenih protiteles cisteina |
-
2017
- 2017-12-21 WO PCT/US2017/067823 patent/WO2018119196A1/en not_active Ceased
- 2017-12-21 CN CN201780079982.XA patent/CN110267685B/zh active Active
- 2017-12-21 JP JP2019533514A patent/JP7170642B2/ja active Active
- 2017-12-21 HU HUE17835533A patent/HUE058664T2/hu unknown
- 2017-12-21 TW TW106145085A patent/TWI783957B/zh active
- 2017-12-21 ES ES17835533T patent/ES2912266T3/es active Active
- 2017-12-21 MD MDE20191243T patent/MD3558391T2/ro unknown
- 2017-12-21 PL PL17835533T patent/PL3558391T3/pl unknown
- 2017-12-21 LT LTEPPCT/US2017/067823T patent/LT3558391T/lt unknown
- 2017-12-21 SM SM20220182T patent/SMT202200182T1/it unknown
- 2017-12-21 EP EP17835533.5A patent/EP3558391B1/en active Active
- 2017-12-21 RS RS20220395A patent/RS63154B1/sr unknown
- 2017-12-21 US US16/469,494 patent/US20210388102A1/en not_active Abandoned
- 2017-12-21 DK DK17835533.5T patent/DK3558391T3/da active
- 2017-12-21 HR HRP20220550TT patent/HRP20220550T1/hr unknown
- 2017-12-21 SI SI201731135T patent/SI3558391T1/sl unknown
- 2017-12-21 PT PT178355335T patent/PT3558391T/pt unknown
-
2022
- 2022-04-27 CY CY20221100306T patent/CY1125181T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504607A5 (enExample) | ||
| JP7585230B2 (ja) | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート | |
| CN101903403B (zh) | Cd19结合剂及其应用 | |
| US12357701B2 (en) | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | |
| JP2017529837A (ja) | 細胞結合剤及び細胞毒性剤を含む複合体 | |
| JP2017536091A (ja) | 多価メディトープ、メディトープ結合性抗体およびそれらの使用 | |
| JP2014516508A (ja) | 抗体−薬剤コンジュゲート | |
| JP6377601B2 (ja) | 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用 | |
| RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
| KR20210102334A (ko) | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 | |
| JP2020532523A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| TW202540197A (zh) | 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症 | |
| JPWO2020086665A5 (enExample) | ||
| US20170326249A1 (en) | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses | |
| JPWO2020005945A5 (enExample) | ||
| JP2022513686A (ja) | グルタミンを含有する軽鎖ｃ末端に伸長部分を含む抗体およびそのコンジュゲートならびにその方法および用途 | |
| RU2832083C2 (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2021100667A (ru) | Иммуноконъюгаты, нацеленные на adam9, и способы их применения | |
| TW202535480A (zh) | 抗cd24抗體藥物結合物及其用途 | |
| RU2023128710A (ru) | Антитела против c-met и коньюгаты антитела с лекарственным средством | |
| RU2025107388A (ru) | Антитела к trop2/egfr и пути их применения | |
| HK40041667A (en) | Anti-her2 biparatopic antibody-drug conjugates and methods of use |